Citadel Advisors’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-4,146
Closed -$5.96K 14703
2026
Q1
$5.96K Sell
4,146
-2,492
-38% -$5.76K ﹤0.01% 12807
2025
Q4
$18.3K Buy
6,638
+3,531
+114% +$21.1K ﹤0.01% 12359
2025
Q3
$29.3K Buy
+3,107
New +$27.1K ﹤0.01% 12403
2025
Q1
Sell
-432
Closed -$11.1K 15432
2024
Q4
$11.1K Buy
+432
New +$14.3K ﹤0.01% 13568
2023
Q4
Sell
-40
Closed -$3.81K 15115
2023
Q3
$3.73K Sell
40
-708
-95% -$91.7K ﹤0.01% 13554
2023
Q2
$134K Buy
748
+211
+39% +$38.6K ﹤0.01% 10497
2023
Q1
$141K Sell
537
-804
-60% -$159K ﹤0.01% 10743
2022
Q4
$206K Buy
1,341
+845
+170% +$148K ﹤0.01% 10080
2022
Q3
$109K Buy
496
+274
+123% +$104K ﹤0.01% 11012
2022
Q2
$106K Buy
+222
New +$80.2K ﹤0.01% 11359

Other funds holding EDVA

Citadel Advisors's EDVA Position: Q2 2026 in Review

Citadel Advisors sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2026, closing a stake of 4,146 shares — an estimated $5.96K sold.

Citadel Advisors first reported a position in EDVA in Q2 2022 and held it in 10 quarters. The position peaked at $206K in Q4 2022. 18 funds tracked by Wall St. Rank hold EDVA as of Q2 2026.

  • Citadel Advisors reported no remaining Endovia Health Sciences, Inc. position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,146 Endovia Health Sciences, Inc. shares in Q2 2026, an estimated $5.96K.
  • Citadel Advisors first reported a position in Endovia Health Sciences, Inc. in Q2 2022 and held it in 10 quarters.
  • Citadel Advisors's Endovia Health Sciences, Inc. position peaked at $206K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.